Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NOL4L divergent transcript (NOL4L-DT) is a long non-coding RNA (lncRNA) gene located near the nucleolar protein 4-like (NOL4L) locus. The “divergent transcript” designation refers to its transcriptional orientation, which is opposite to a nearby protein-coding gene from a shared promoter region—a feature common in mammalian genomes where transcription occurs in both directions from a promoter[7]. While the protein-coding gene NOL4L has been implicated in some fusion events in acute leukemia, the function, expression profile, and clinical relevance of NOL4L-DT remain unknown. Available evidence from databases and gene annotations indicates that NOL4L-DT does not encode a protein and currently has no established biological or therapeutic role[5][1][3][7]. - No PDB structure exists for NOL4L-DT. - No documented Gene Ontology (GO) functional annotations beyond general RNA/protein binding for this lncRNA[1][5]. - Most information comes from genome-wide annotation databases rather than experimental studies. If you require information on the protein-coding NOL4L gene (nucleolar protein 4-like), more is known regarding its location, expression pattern, and rare involvement in gene fusions in leukemia[3]; however, the “NOL4L divergent transcript” specifically refers to a noncoding RNA gene without well-characterized function or disease association[5].
Not applicable, as there are no known drugs targeting this transcript
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NOL4L divergent transcript (NOL4L-DT).